Efficacy of vibegron in patients with overactive bladder: Multicenter prospective study of real‐world clinical practice in Japan, SCCOP study 19‐01
- 28 October 2021
- journal article
- research article
- Published by Wiley in LUTS: Lower Urinary Tract Symptoms
- Vol. 14 (2) , 109-116
Abstract
Objective: To evaluate the efficacy and safety of vibegron in patients with overactive bladder (OAB) in real‐world clinical practice in Japan.Methods: This multicenter, prospective, non‐controlled study consecutively enrolled patients with OAB determined by an OAB symptom score (OABSS) of three points or more and a question 3 (urgency) score of two points or more. A total of 212 patients from 43 institutions were recruited from January 2019 through March 2020. Vibegron, 50 mg, was administrated daily for 8 weeks as first‐line monotherapy (first‐line group, FL), monotherapy switching from antimuscarinics (post‐antimuscarinic group, PA) or mirabegron (post‐mirabegron group, PM) and combination therapy with antimuscarinics (add‐on group). The OABSS was collected at baseline and every 2 weeks. Adverse events were recorded at every visit.Results: Of the 212 patients registered, 188 (male 76, female 112) were eligible for analysis (124 in the FL group, 27 in PA, 29 in PM, and eight in the add‐on group). The add‐on group was excluded from further analysis due to its small number. The OABSS (mean ± SD) showed significant improvement in all groups (FL; 8.8 ± 2.5, 3.8 ± 2.8, PM; 9.4 ± 2.2, 4.5 ± 4.0, PM; 8.9 ± 2.5, 4.7 ± 3.3 at 0 and 8 weeks, respectively). The overall incidence of adverse events was 25%. No grade 3 or higher adverse events were observed.Conclusions: In the real‐world clinical setting, vibegron is effective and well‐tolerated by OAB patients, including those switching therapy from antimuscarinics and mirabegron.Keywords
This publication has 25 references indexed in Scilit:
- Mirabegron in overactive bladder: A review of efficacy, safety, and tolerabilityNeurourology and Urodynamics, 2013
- Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive BladderEuropean Urology, 2013
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in menInternational Urology and Nephrology, 2012
- Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experienceBJU International, 2012
- Assessment of lower urinary tract symptoms in men by international prostate symptom score and core lower urinary tract symptom scoreBJU International, 2011
- Assessment of Overactive Bladder Symptoms: Comparison of 3-Day Bladder Diary and the Overactive Bladder Symptoms ScoreUrology, 2011
- Risk factors for overactive bladder in the elderly population: A community‐based study with face‐to‐face interviewInternational Journal of Urology, 2010
- Symptom severity and patient perceptions in overactive bladder: how are they related?BJU International, 2009
- An epidemiological survey of overactive bladder symptoms in JapanBJU International, 2005